BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghanbari R, Teimoori A, Sadeghi A, Mohamadkhani A, Rezasoltani S, Asadi E, Jouyban A, Sumner SC. Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients. Future Microbiol 2020;15:1747-58. [PMID: 33404263 DOI: 10.2217/fmb-2020-0120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Chrzastek K, Tennakoon C, Bialy D, Freimanis G, Flannery J, Shelton H. A random priming amplification method for whole genome sequencing of SARS-CoV-2 virus. BMC Genomics 2022;23. [DOI: 10.1186/s12864-022-08563-z] [Reference Citation Analysis]
2 Saravanan KA, Panigrahi M, Kumar H, Rajawat D, Nayak SS, Bhushan B, Dutt T. Role of genomics in combating COVID-19 pandemic. Gene 2022;823:146387. [PMID: 35248659 DOI: 10.1016/j.gene.2022.146387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Petrou A, Zagaliotis P, Theodoroula NF, Mystridis GA, Vizirianakis IS, Walsh TJ, Geronikaki A. Thiazole/Thiadiazole/Benzothiazole Based Thiazolidin-4-One Derivatives as Potential Inhibitors of Main Protease of SARS-CoV-2. Molecules 2022;27:2180. [DOI: 10.3390/molecules27072180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Singla S, Goyal S. Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences. Bull Natl Res Cent 2022;46. [DOI: 10.1186/s42269-022-00753-9] [Reference Citation Analysis]
5 Rani P, Kapoor B, Gulati M, Atanasov AG, Alzahrani Q, Gupta R. Antimicrobial peptides: A plausible approach for COVID-19 treatment. Expert Opin Drug Discov 2022;:1-15. [PMID: 35255763 DOI: 10.1080/17460441.2022.2050693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pászti-Gere E, Szentkirályi A, Fedor Z, Nagy G, Szimrók Z, Pászti Z, Pászti A, Pilgram O, Steinmetzer T, Bodnárová S, Fliszár-Nyúl E, Poór M. In vitro interaction of potential antiviral TMPRSS2 inhibitors with human serum albumin and cytochrome P 450 isoenzymes. Biomed Pharmacother 2021;146:112513. [PMID: 34915414 DOI: 10.1016/j.biopha.2021.112513] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Li G, De Oliveira DMP, Walker MJ. The antimicrobial and immunomodulatory effects of Ionophores for the treatment of human infection. J Inorg Biochem 2021;227:111661. [PMID: 34896767 DOI: 10.1016/j.jinorgbio.2021.111661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
8 Marín-Palma D, Tabares-Guevara JH, Zapata-Cardona MI, Flórez-Álvarez L, Yepes LM, Rugeles MT, Zapata-Builes W, Hernandez JC, Taborda NA. Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms. Molecules 2021;26:6900. [PMID: 34833991 DOI: 10.3390/molecules26226900] [Reference Citation Analysis]
9 Shagufta, Ahmad I. An Update on Pharmacological Relevance and Chemical Synthesis of Natural Products and Derivatives with Anti SARS-CoV-2 Activity. ChemistrySelect 2021;6:11502-27. [PMID: 34909460 DOI: 10.1002/slct.202103301] [Reference Citation Analysis]
10 Janissen R, Woodman A, Shengjuler D, Vallet T, Lee KM, Kuijpers L, Moustafa IM, Fitzgerald F, Huang PN, Perkins AL, Harki DA, Arnold JJ, Solano B, Shih SR, Vignuzzi M, Cameron CE, Dekker NH. Induced intra- and intermolecular template switching as a therapeutic mechanism against RNA viruses. Mol Cell 2021;81:4467-4480.e7. [PMID: 34687604 DOI: 10.1016/j.molcel.2021.10.003] [Reference Citation Analysis]
11 Pedler RL, Speck PG. Marine mollusc extracts-Potential source of SARS-CoV-2 antivirals. Rev Med Virol 2021;:e2310. [PMID: 34726308 DOI: 10.1002/rmv.2310] [Reference Citation Analysis]
12 Iype E, Pillai U J, Kumar I, Gaastra-Nedea SV, Subramanian R, Saha RN, Dutta M. In silico and in vitro assays reveal potential inhibitors against 3CLpro main protease of SARS-CoV-2. J Biomol Struct Dyn 2021;:1-12. [PMID: 34550861 DOI: 10.1080/07391102.2021.1977181] [Reference Citation Analysis]
13 Ahn JH, Kim J, Hong SP, Choi SY, Yang MJ, Ju YS, Kim YT, Kim HM, Rahman MDT, Chung MK, Hong SD, Bae H, Lee CS, Koh GY. Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19. J Clin Invest 2021;131:148517. [PMID: 34003804 DOI: 10.1172/JCI148517] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Monzavi SM, Naderi M, Ahmadbeigi N, Kajbafzadeh AM, Muhammadnejad S. An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19. Cell Immunol 2021;367:104398. [PMID: 34217004 DOI: 10.1016/j.cellimm.2021.104398] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Abramenko N, Vellieux F, Tesařová P, Kejík Z, Kaplánek R, Lacina L, Dvořánková B, Rösel D, Brábek J, Tesař A, Jakubek M, Smetana K Jr. Estrogen Receptor Modulators in Viral Infections Such as SARS-CoV-2: Therapeutic Consequences. Int J Mol Sci 2021;22:6551. [PMID: 34207220 DOI: 10.3390/ijms22126551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]